TABLE 3.
Prevalence of Pfdhfr and Pfdhps single and haplotype mutations among women on SP-IPTpa
| Pfdhfr and Pfdhps haplotype(s) | Prevalence of Pfdhfr and Pfdhps mutations atb: |
||
|---|---|---|---|
| First ANC visit (baseline sample) | Second ANC visit (after one SP dose) | Delivery (after two SP doses) | |
| dhfr 51I | 56/57 (98.2) | 13/13 (100) | 9/9 (100) |
| dhfr 59R | 74/83 (89.2) | 18/18 (100) | 9/10 (90) |
| dhfr 108N | 105/105 (100) | 23/23 (100) | 14/14 (100) |
| dhps 437G | 116/117 (99.1) | 26/26 (100) | 14/15 (93.3) |
| dhps 540E | 107/109 (98.2) | 24/24 (100) | 14/15 (93.3) |
| dhps 581G | 2/61 (3.3) | 2/16 (12.5) | 0/9 (0) |
| dhps 613S | 0/74 (0) | 0/18 (0) | 0/10 (0) |
| dhfr double mutant 51I+108N | 56/57 (98.2) | 13/13 (100) | 9/9 (100) |
| dhfr double mutant 59R+108N | 74/83 (89.2) | 18/18 (100) | 9/10 (90) |
| dhps double mutant 437G+540E | 107/109 (98.2) | 24/24 (100) | 14/15 (93.3) |
| dhfr triple mutant 51I+59R+108N | 49/54 (90.7) | 13/13 (100) | 7/8 (87.5) |
| Quadruple mutant (51I+59R+108N)+437G | 49/54 (90.7) | 13/13 (100) | 6/8 (75) |
| Quintuple mutant (51I+59R+108N)+(437G+540E) | 48/54 (88.9) | 13/13 (100) | 6/8 (75) |
| Sextuple mutant (51I+59R+108N)+(437G+540E+581G) | 2/52 (3.9) | 2/12 (16.7) | 0/8 (0) |
a
The proportions of P. falciparum-positive mutations were as follows: first ANC visit, 55(4.2%); second ANC visit, 26 (2.0%); and delivery, 22 (1.7%). SP, sulfadoxine-pyrimethamine; IPTp, intermittent preventive treatment.
b
Prevalence data are expressed as follows: number of mutations/total number of samples tested (%).